- Home
- NAMS vs WD Comparison
NAMS vs WD Comparison
Compare NAMS & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- WD
- Stock Information
- Founded
- NAMS 2019
- WD 1937
- Country
- NAMS Netherlands
- WD United States
- Employees
- NAMS N/A
- WD N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- WD Finance: Consumer Services
- Sector
- NAMS Health Care
- WD Finance
- Exchange
- NAMS Nasdaq
- WD Nasdaq
- Market Cap
- NAMS 2.7B
- WD 2.4B
- IPO Year
- NAMS N/A
- WD 2010
- Fundamental
- Price
- NAMS $26.73
- WD $87.58
- Analyst Decision
- NAMS Strong Buy
- WD Buy
- Analyst Count
- NAMS 10
- WD 2
- Target Price
- NAMS $41.40
- WD $102.50
- AVG Volume (30 Days)
- NAMS 984.0K
- WD 227.9K
- Earning Date
- NAMS 11-05-2025
- WD 11-06-2025
- Dividend Yield
- NAMS N/A
- WD 3.10%
- EPS Growth
- NAMS N/A
- WD 25.06
- EPS
- NAMS N/A
- WD 3.24
- Revenue
- NAMS $64,006,000.00
- WD $1,111,017,000.00
- Revenue This Year
- NAMS N/A
- WD $18.16
- Revenue Next Year
- NAMS $1.67
- WD $5.63
- P/E Ratio
- NAMS N/A
- WD $26.72
- Revenue Growth
- NAMS 762.15
- WD 15.06
- 52 Week Low
- NAMS $14.06
- WD $64.48
- 52 Week High
- NAMS $27.35
- WD $118.19
- Technical
- Relative Strength Index (RSI)
- NAMS 59.23
- WD 59.95
- Support Level
- NAMS $23.05
- WD $84.49
- Resistance Level
- NAMS $27.35
- WD $88.47
- Average True Range (ATR)
- NAMS 1.52
- WD 2.00
- MACD
- NAMS -0.11
- WD -0.25
- Stochastic Oscillator
- NAMS 85.58
- WD 87.57
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.